经ISO 9001:2015 和 ISO 13485:2016认证
生产厂房具备药品生产许可证
药品B+A级洁净室和自动灌装设备
无菌技术与二级除菌过滤
无动物源性材料和生产环境
人员培训体系
供应商和原材料管理体系
质量文件/记录经QA审查和批准
完整的批生产和检验记录
设备维护和校准程序
分析方法的验证
完整的法规支持文档(RSF)
细胞活性高于0.8 x 107 IU/mg
纯度高于95%
内毒素低于10EU/mg
宿主DNA残留低于0.02ng/ug
宿主蛋白残留低于0.5ng/ug
无菌检测
支原体检测
外源病毒检测
高批间一致性
全面的稳定性数据支持(加速,冻融,长期,运输稳定性验证)
体内安全性数据
药典标准放行
- 16项质量控制指标
- 更好的安全性(无菌,支原体,外源病毒,各项杂质残留检测)
- 高稳定性和批间一致性
更严格GMP质量管理体系
- 药品级生产厂房
- 药用级物料/包材
- 支持线上/线下审计
加速临床/上市申报
- 完整的细胞/基因治疗产品申报支持文档
- 提供全套方法学验证报告
- 已完成FDA DMF备案
分子 | 货号 | 产品描述 | 订购/预购 |
---|---|---|---|
IL-15 | GMP-L15H13 | GMP Human IL-15 | |
IL-7 | GMP-L07H24 | GMP Human IL-7 | |
IL-21 | GMP-L21H25 | GMP Human IL-21 |
分子 | 货号 | 产品描述 | 订购/预购 |
---|---|---|---|
CD3 | GMP-MC0323 | GMP Monoclonal Anti-Human CD3 Antibody(OKT3) | |
CD28 | GMP-MC2824 | GMP Monoclonal Anti-Human CD28 Antibody | |
BenzNuclease | GMP-NUES19 | GMP GENIUS™ Nuclease | |
Cas9 | GMP-CA9S19 | GMP NLS-Cas9 Nuclease |
SDS-PACE 纯度>95%
刺激CTLL-2 细胞增殖实验结果显示,GMP Human IL-15 (GMP-L15H13)的细胞活性高于0.8 ⅹ10^7 IU/mg(经WHO Human IL-15标品校准,NIBSC 代码:95/554)。
ACROBiosystems GMP grade products are produced under a quality management system and in compliance with relevant guidelines: Ph. Eur General Chapter 5.2.12 Raw materials of biological origin for the production of cell-based and gene therapy medicinal products; USP <92> Growth Factors and Cytokines Used in Cell Therapy Manufacturing; USP <1043> Ancillary Materials for Cell, Gene, and Tissue-Engineered Products; ISO/TS 20399-1:2018, Biotechnology - Ancillary Materials Present During the Production of Cellular Therapeutic Products.
ACROBiosystems Quality Management System Contents:
ACROBiosystems provide rigorous quality control tests (fully validated equipment, processes and test methods) on our GMP grade products to ensure that they meet stringent standards in terms of purity, safety, activity and inter-batch stability, and each bulk QC lot mainly contains the following specific information:
ACROBiosystems GMP grade products are designed for research, manufacturing use or ex vivo use. CAUTION: Not intended for human in vivo applications.
All products are warranted to meet ACROBiosystems Inc.’s (“ACRO”) published specifications when used under normal laboratory conditions.
ACRO DOES NOT MAKE ANY OTHER WARRANTY OR REPRESENTATION WHATSOEVER, WHETHER EXPRESS OR IMPLIED, WITH RESPECT TO ITS PRODUCTS. IN PARTICULAR, ACRO DOES NOT MAKE ANY WARRANTY OF SUITABILITY, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE.
NOT WITH STANDING ANY OTHER PROVISIONS OF THESE TERMS AND/OR ANY OTHER AGREEMENT BETWEEN ACRO AND PURCHASER FOR THE PURCAHSE OF THE PRODUCTS, ACRO’S TOTAL LIABILITY TO PURCHASER ARISING FROM OR IN RELATION TO THESE TERMS, AN AGREEMENT BETWEEN THE PARTIES OR THE PRODUCTS, WHETHER ARISING IN CONTRACT, TORT OR OTHERWISE SHALL BE LIMITED TO THE TOTAL AMOUNT PAID BY PURCHASER TO ACRO FOR THE RELEVANT PRODUCTS. IN NO EVENT WILL ACRO BE LIABLE FOR THE COST OF PROCUREMENT OF SUBSTITUTE GOODS.
The following terms are offered to you upon your acceptance of these End User Terms of Use of Product. By using this product, you indicate your acknowledgment and agreement to these End User Terms of Use of Product. If you do not agree to be bound by and comply with all of the provisions of these End User Terms of Use of Product, you should contact your supplier of the product and make arrangements to return the product.
The End User is aware that ACROBiosystems Inc. and its affiliate (“ACRO”) sell GMP grade products designed for research, manufacturing use or ex vivo use and not intended for human in vivo applications. The End User further agrees, as a condition of the sales of ACRO’s GMP grade products that: a) the End User will not use this GMP grade product in any procedure wherein the product may be directly or indirectly administered to humans, unless the End User has obtained, or prior to their use will have obtained, an Investigational New Drug (IND) exemption from the FDA and will use the product only in accordance with the protocols of such IND and of the Institutional Review Board overseeing the proposed research, or b) the End User will use the products outside of the United States in accordance with the protocols of research approved by the applicable review board or authorized ethics committee and regulatory agencies to which the End User is subject to in their territory.